HEMATOLOGY

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

Abdulraheem Yacoub, MD, discusses imetelstat as a newer and exciting option for patients with myelodysplastic syndromes.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

Noah M. Merin, MD, PhD, discusses approved therapies in acute and chronic graft-vs-host disease.

Michael J. Mauro, MD, discusses decision-making for patients with chronic myeloid leukemia.

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

The REMARK trial aims to assess the safety and efficacy of RVU120 in patients with lower-risk myelodysplastic syndromes.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.

ICT01 showed tolerable safety and promising clinical activity as a monotherapy and is now being investigated in combination with azacitidine and venetoclax in AML.

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

Denileukin diftitox, an IL-2-receptor-directed cytotoxin, has been added to the NCCN guidelines for the treatment of adult patients with cutaneous T-cell lymphoma.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory disease and long-term follow-up of pivotal trials.

An expert on myelodysplastic syndromes reviews recent real-world data presented at EHA 2024 showing the clinical benefit of luspatercept dose titration.

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS.

A hematologist-oncologist discusses the efficacy and safety findings from the COMMANDS trial and how they inform treatment selection.

Solly Chedid, MD, presents a patient case and provides clinical insights on approaching first-line therapy selection in patients with LR-MDS and moderate to severe anemia.